Results 31 to 40 of about 1,078,518 (304)

Cost‐utility analysis of radiofrequency ablation versus optimal medical therapy in managing supraventricular tachycardia among Filipinos

Journal of Arrhythmia, 2023
Background Radiofrequency ablation (RFA) is the standard of care in the management of supraventricular tachycardia (SVT). Its cost‐effectiveness in an emerging Asian country has not been studied.
Giselle G. Gervacio, Miharu J. M. Kimwell, Erdie C. Fadreguilan, Denese C. De Guzman, E. A. Gabriel, Clara S. Tolentino, Gladys R. S. David   +6 more
doaj   +1 more source

Cost-utility analysis: Incremental cost-effectiveness ratio (ICER)—base case.

, 2019
Cost-utility analysis: Incremental cost-effectiveness ratio (ICER)—base case.
Frauke Becker (2836922), Denise Howel (16468), Catherine Haighton (2157001), Martin White (16466), Andrew Bryant (5704967), Terry Aspray (6194804), Luke Vale (3435356), Elaine McColl (533649), Suzanne Moffatt (16467), Sarah Lawson (6194801), Melanie Steer (6194798), Eugene M. G. Milne (2215138)   +11 more
core   +1 more source

The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study)

BMC Medical Informatics and Decision Making, 2021
Background Tumor necrosis factor α inhibitors (TNFi) is effective for rheumatoid arthritis (RA) patients who fail to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).
Juan Zhao, Wei Zhou, Yangfeng Wu, Ping Ji, Li Yang, Xiaoyan Yan, Zhuoli Zhang   +6 more
doaj   +1 more source

Time Toxicity in Wilms Tumor: Quantifying the Burden of Healthcare Interaction in the First Year After Diagnosis

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Wilms tumor (WT) treatment imposes a significant time burden on patients and their families. Time toxicity is a patient‐centered metric that quantifies the burden of healthcare interaction. We sought to define time toxicity in the first year after diagnosis of WT and hypothesized that it would increase as tumor stage and treatment ...
Caleb Q. Ashbrook, Veerain Gupta, Nicholas J. Clark, Vijay Rings, Lauren E. Corona, Douglass B. Clayton, Daniel J. Benedetti   +6 more
wiley   +1 more source

A Systematic Review of Economic Evaluations of Active Tuberculosis Treatments

Frontiers in Pharmacology, 2021
Background: The disease burden of active tuberculosis (TB) is considerable, but systematic reviews of economic evaluations of active TB treatments are scarce.Methods: PubMed, EMBASE, and the Cochrane Library databases were used to search for articles on ...
Joo-Young Byun, Hye-Lin Kim, Eui-Kyung Lee, Sun-Hong Kwon   +3 more
doaj   +1 more source

A Bibliometric Analysis of Publications in Uremic Toxins From 1991 to 2024

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Uremic toxins are a growing area of research in nephrology, with significant implications in the progression and treatment of chronic kidney disease (CKD) and the management of end‐stage kidney disease (ESKD). This bibliometric analysis aims to evaluate the global research trends, key contributors, and the impact of publications in ...
Yuh‐Shan Ho, Karim M. Soliman, Wisit Cheungpasitporn, Wannasit Wathanavasin, Ahmed Daoud, Ahmed I. Kamal, Balázs Szamosfalvi, Tibor Fülöp   +7 more
wiley   +1 more source

Cost-utility analysis of ceftolozane/tazobactam vs meropenem in patients with hospital-acquired pneumonia (HABP) or ventilator-associated pneumonia (VABP)

Global & Regional Health Technology Assessment, 2022
Obiettivo: Questo studio ha lo scopo di valutare il rapporto costo-efficacia di ceftolozano/tazobactam rispetto a meropenem per il trattamento di pazienti con polmonite acquisita in ospedale (HABP) o polmonite associata a ventilazione meccanica (VABP ...
Francesco Saverio Mennini, Martina Paoletti, Chiara Bini, Andrea Marcellusi, Marco Falcone, Massimo Andreoni   +5 more
doaj   +1 more source

Therapeutic Apheresis in Nigeria: A Multi‐Center Summary of Abstracts From the Inaugural Nigerian Society for Apheresis Scientific Meeting

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Therapeutic apheresis (TA) is an established treatment modality for hematologic, neurologic, and immunologic disorders, yet access remains severely limited in sub‐Saharan Africa. Donor apheresis, including platelet apheresis collection from healthy donors, represents an important complementary modality supporting blood product ...
Nosa Bazuaye, Chimezie Okwuonu, Evelyn Idam, Folasade Adelekan‐Popoola, Shakirat Gold‐Olufadi, Olufunto Olufela Kalejaiye, Abdullateef Ogala, Zinnah Aloziem, Blossom Amamchukwu, Patience Elimia, Mkpoikanabasi Obot‐Obot, Henry Mbakwe, Praises Maduagwuna, Olatunji Akinrodoye, Chiamaka Anyanwu, Benjamin Anyanwu, Adedamola Akinsiku, Oluwatoyin A. Akinsiku, Muzamil O. Hassan, Fatiu A. Arogundade, Olalekan E. Ojo, Homayemem Weli, Jesupelumi Adenihun, Aderemi Adelaja, Ebun Bamgboye, Olalekan Olatise, Ade E. Faponle, Ayoola Odeyemi, Michael Muoka, Stephen Asaolu, Qudrat Busari, Blessing Dawudu, Michael Naiyeju, Rasheed A. Balogun   +33 more
wiley   +1 more source

Optimising risk reduction: An expected utility approach for marginal risk reduction during regulatory decision making [PDF]

, 2009
In practice, risk and uncertainty are essentially unavoidable in many regulation processes. Regulators frequently face a risk-benefit trade-off since zero risk is neither practicable nor affordable.
Kendall, Graham, Pollard, Simon, Li, Jiawei W., Davies, Gareth, Soane, Emma, Davies, Gareth J., Li, Jiawei, Pollard, Simon J. T.   +7 more
core   +1 more source

Establishing an Apheresis Medicine Program in a Resource‐Constrained Setting: A 5‐Year Experience From Lagos, Nigeria

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Establishing a comprehensive apheresis medicine program in a resource‐constrained setting presents significant structural, financial, and logistical challenges. Despite the growing clinical importance of apheresis services globally, published experience from sub‐Saharan Africa remains sparse.
Folasade Adelekan‐Popoola, Shakirat Gold‐Olufadi, Olufunto Olufela Kalejaiye, Abdullateef Ogala, Rasheed A. Balogun   +4 more
wiley   +1 more source